Mirtazapine: Pharmacology in relation to adverse effects

Acta Psychiatrica Scandinavica

Volumn 96, Issue SUPPL.391, 1997, Pages 31-37

  Nutt, D ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Adverse event; Antidepressant; Mirtazapine

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; DRUG DERIVATIVE; MIANSERIN; MIRTAZAPINE; SEROTONIN; SEROTONIN RECEPTOR; MUSCARINIC AGENT;

ARTICLE; DRUG EFFECT; HUMAN; PHYSIOLOGY; SYNAPSE; CONFERENCE PAPER; DEPRESSION; ENZYME INHIBITION; NAUSEA; NORADRENERGIC SYSTEM; SEROTONIN BLOOD LEVEL; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION;

ADRENERGIC ALPHA-ANTAGONISTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; HUMANS; MIANSERIN; RECEPTORS, SEROTONIN; SEROTONIN; SYNAPSES;

EID: 0030630385     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1997.tb05956.x     Document Type: Article

References (21)

1. Svensson TH. Bunney BS, Aghajanian GK. Inhibition of both NA and 5-HT neurons in brain by the oc-adrenergic agonist clonidine. Brain Res 1975: 92: 291-306.
2. Baraban JM, Aghajanian GK. Suppression of firing activity of 5-HT neurons in the dorsal raphe by a-adrenoceptor antagonists. Neuropharmacology 1980: 19: 355-363.
3. A mediated serotonergic neurotransmission. CNS Drugs 1995: 4(suppl 1): 29-38.
4. Haddjeri N, Blier P, De Montigny C. Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. Int Clin Psychopharmacol 1995: 10(suppl 4): 11-17.
5. de Boer T, Nefkens F, Van Helvoirt A, Van Delfi AM. Differences in modulation of noradrenergic and serotonergic transmission by the (^-adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther 1996: 227: 852-277.
6. Hoyer D, Clarke DE, Fozard JR et al. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994: 46: 157-204.
7. 7 serotonin receptors: molecular biology and pharmacology. Neurotransmitters 1995: 11: 1-5.
8. 1A receptors. Br J Pharmacol 1993: 108: 669-677.
9. 1A receptor agonist in treatment-resistant depression. Int Clin Psychopharmacol 1993: 8: 167-172.
10. de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996: 57(suppl 4): 19-26.
11. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993: 52: 1023-1029.
12. Stahl S, Zivkov M, Reimitz P-E, Panagides J, Hoff W. Meta-analysis of randomized, double-blind, placebo-controlled efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Acta Psychiatr Scand 1997: 95(suppl 391): 22-30.
13. 2 receptor subtypes: central localisation,roles and possible therapeutic applications of agonists and antagonists. Eur Neuropsychopharmacol 1996: 6(suppl 4): 40-41.
14. Lawlor BA, Newhouse PA, Balkin TJ et al. A preliminary study of the effects of nighttime administration of the serotonin agonist mCPP on sleep architecture and behaviour in healthy volunteers, Biol Psychiatry 1990: 29: 281-286.
15. Idzikowski C, Cowen PJ, Nutt DJ, Mills FJ. The effects of chronic ritanserin treatment on sleep and the neuro-endocrine response to L-tryptophan. Psychopharmacol 1987: 93: 416-420.
16. Davidson JRT. Sexual dysfunction and antidepressants. Depression 1994/1995: 2: 233-240.
17. Arnott S, Nun' DJ. Successful treatment of fluvoxamine-induced anorgasmia by cyproheptadine. Br J Psychiatry 1994: 164: 838-839.
18. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995: 10(suppl 4): 37-45.
19. Bailey JE, Potokar J, Coupland NJ, Nutt DJ. The 5-HT, antagonist ondansetron reduces gastrointestinal side effects induced by a specific serotonin re-uptake inhibitor in man. J Psychopharmacol 1995: 9: 137-141.
20. Hoes MJAJM, Zupfei.d JHB. First report of mirtazapine overdose. Int Clin Psychopharmacol 1996: 11: 147.
21. Zivkov M, Kremer CME, Hoes MJAJM, Blokland E, Helsdingen JT. Safety of mirtazapine in overdose. Eur Neuropsychopharmacol 1996: 6(suppl 4): 62.